Collplant successfully bio-prints 200cc commercial-size regenerative breast implants and reports additional positive pre-clinical data

Bio-printing technology now enables fabrication of 200cc implant size and above to address future commercial demand interim pre-clinical data shows tissue growth including regeneration of maturing connective tissue as well as neovascularization, synchronized with progressive implant degradation no adverse tissue reaction was observed large-animal studies with commercial-size implants are currently underway with results expected in q4 2024 and q1 2025 rehovot, israel , june 6, 2024 /prnewswire/ -- collplant biotechnologies (nasdaq: clgn), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived recombinant human collagen (rhcollagen) for tissue regeneration and organ manufacturing, today announced that it has successfully printed for the first-time breast implants of 200 cc, which are commercial size. these implants were printed using collplant's proprietary rhcollagen bioinks.
CLGN Ratings Summary
CLGN Quant Ranking